spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  2ME2 

 HSMN NewsFeed - 21 Sep 2015
CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Mar 2015
CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
EntreMed Appoints Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2007
EntreMed Raises $20 Million to Support Clinical Development Program
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
EntreMed Commences Clinical Trial for MKC-1 in Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
EntreMed Commences Panzem(R) NCD Phase 2 Study in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 May 2006
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
2ME2
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.